Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

CLEIA CA125 evidences: good analytical performance avoiding "Hook effect".

Falzarano R, Viggiani V, Michienzi S, Colaprisca B, Longo F, Frati L, Anastasi E.

Tumour Biol. 2013 Feb;34(1):387-93. doi: 10.1007/s13277-012-0561-6. Epub 2012 Nov 1.

PMID:
23111756
[PubMed - indexed for MEDLINE]
2.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
[PubMed - indexed for MEDLINE]
3.

Technical and clinical comparison of two fully automated methods for the immunoassay of CA 125 in serum.

Yan G, Ju H, Liang Z, Zhang T.

J Immunol Methods. 1999 May 27;225(1-2):1-8.

PMID:
10365777
[PubMed - indexed for MEDLINE]
4.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
[PubMed - indexed for MEDLINE]
5.

Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.

Park Y, Kim Y, Lee EY, Lee JH, Kim HS.

Int J Cancer. 2012 Mar 1;130(5):1136-44. doi: 10.1002/ijc.26129. Epub 2011 Jun 14.

PMID:
21484794
[PubMed - indexed for MEDLINE]
6.

New tumor markers: CA125 and beyond.

Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K.

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81. Review.

PMID:
16343244
[PubMed - indexed for MEDLINE]
7.

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel Dxl 800 Immunoassay System.

Holdenrieder S, Molina R, Gion M, Gressner A, Troalen F, Auge JM, Zancan M, Wycislo M, Stieber P.

Clin Chem Lab Med. 2008;46(5):588-99. doi: 10.1515/CCLM.2008.125.

PMID:
18598201
[PubMed - indexed for MEDLINE]
8.

Evaluation of a CLEIA automated assay system for the detection of a panel of tumor markers.

Falzarano R, Viggiani V, Michienzi S, Longo F, Tudini S, Frati L, Anastasi E.

Tumour Biol. 2013 Oct;34(5):3093-100. doi: 10.1007/s13277-013-0877-x. Epub 2013 Jun 18.

PMID:
23775009
[PubMed - indexed for MEDLINE]
9.

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.

Zheng H, Gao Y.

Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.

PMID:
22426406
[PubMed - indexed for MEDLINE]
10.

Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.

Davelaar EM, Schutter EM, von Mensdorff-Pouilly S, van Kamp GJ, Verstraeten RA, Kenemans P.

Ann Clin Biochem. 2003 Nov;40(Pt 6):663-73.

PMID:
14629806
[PubMed - indexed for MEDLINE]
11.

Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers.

Nishizono I, Iida S, Suzuki N, Kawada H, Murakami H, Ashihara Y, Okada M.

Clin Chem. 1991 Sep;37(9):1639-44.

PMID:
1716538
[PubMed - indexed for MEDLINE]
Free Article
12.

Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.

Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC Jr, Mills GB.

Cancer. 1995 Nov 1;76(9):1615-20.

PMID:
8635066
[PubMed - indexed for MEDLINE]
13.

[Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].

Lapchenkov VI, Dudarev AL, Vinokurov VL, Iurkova LE, Barbanel EIu.

Vestn Rentgenol Radiol. 1993 Sep-Oct;(5):30-1. Russian.

PMID:
7801580
[PubMed - indexed for MEDLINE]
14.

LyGDI is a promising biomarker for ovarian cancer.

Zhen H, Yang S, Wu H, Wang S, Lv J, Ma L, Zhang X.

Int J Gynecol Cancer. 2010 Apr;20(3):316-22. doi: 10.1111/IGC.0b013e3181d0b02d.

PMID:
20375790
[PubMed - indexed for MEDLINE]
15.

The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.

Yang J, Sa M, Huang M, Yang J, Xiang Z, Liu B, Tang A.

Clin Biochem. 2013 Nov;46(16-17):1705-8. doi: 10.1016/j.clinbiochem.2013.08.019. Epub 2013 Sep 6.

PMID:
24012857
[PubMed - indexed for MEDLINE]
16.

Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.

Tamakoshi K, Kikkawa F, Hasegawa N, Ishikawa H, Mizuno K, Kawai M, Tomoda Y.

Gynecol Obstet Invest. 1995;39(2):125-9.

PMID:
7737582
[PubMed - indexed for MEDLINE]
17.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
[PubMed - indexed for MEDLINE]
18.

Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.

Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A.

Cancer. 2002 Nov 1;95(9):1886-93.

PMID:
12404282
[PubMed - indexed for MEDLINE]
Free Article
19.

[CA125].

Kuzuya K, Kuwabara M, Ariyoshi Y.

Nihon Rinsho. 2005 Aug;63 Suppl 8:637-41. Review. Japanese. No abstract available.

PMID:
16149599
[PubMed - indexed for MEDLINE]
20.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

PMID:
15734951
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk